Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success

 
• By Lucie Ellis-Taitt
  
Cancer cells
Erytech's positive pancreatic cancer data could push the company towards other solid tumor indications

More from Clinical Trials

More from R&D